Diacetylputrescine and its analog suppress c-myc expression and activation of human B-lymphocytes.
Our studies demonstrate that diacetylputrescine (TMBA), and its analog hexamethylenebisacetamide, HMBA, inhibit the expression of the c-myc oncogene in activated human B-lymphocytes. Activation of human B-cells induced by anti-IgM is associated with the induction of c-myc by greater than 20 times basal levels, maximal levels occurring at about 2 hours. This increased c-myc expression is inhibited by greater than 90% by 3 mM TMBA or 3mM HMBA. TMBA and HMBA also inhibit by greater than 90% the subsequent activation of the B-cells. These diacetylated polyamines may play a regulatory role in B-cell activation.
Luk
G D
GD
Department of Medicine, Wayne State University School of Medicine, Detroit, Michigan 48201.
Canellakis
Z N
ZN
D000081:Acetamides / Q000494:pharmacology*; D001402:B-Lymphocytes / Q000378:metabolism*; D002455:Cell Division; D005786:Gene Expression Regulation / Q000187:drug effects*; D006801:Humans; D007700:Kinetics; D008213:Lymphocyte Activation / Q000187:drug effects; D009857:Oncogenes; D011519:Proto-Oncogenes; D011700:Putrescine / Q000031:analogs & derivatives* / Q000494:pharmacology
D000081:Acetamides; C063620:diacetylputrescine; C014026:hexamethylene bisacetamide; D011700:Putrescine